시장보고서
상품코드
1954260

롱리드 시퀀싱 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 컴포넌트별, 디바이스별, 프로세스별, 전개 모드별, 모드별(-2035년)

Long Read Sequencing Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Device, Process, Installation Type

발행일: | 리서치사: Global Insight Services | 페이지 정보: 영문 334 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

롱리드 시퀀싱 시장은 2024년 24억 달러에서 2034년까지 91억 달러로 확대될 전망이며, CAGR 약 12.2%를 나타낼 것으로 예측됩니다. 롱리드 시퀀싱 시장은 긴 DNA 또는 RNA 단편을 읽을 수 있는 고급 유전체 시퀀싱 기술을 포함하여 복잡한 유전자 구조에 대한 종합적인 발견을 제공합니다. 이 시장은 정밀의료, 맞춤형 의료, 유전체 연구에 대한 수요에 의해 견인되고 있습니다. 주요 용도로는 희귀질환 진단, 암 유전체학, 농업 생명공학 등이 있습니다. 혁신은 연구자와 의료 제공업체가 상세한 유전자 정보를 필요로 하는 요구에 대응하고 정확성, 속도 및 비용 효율성 향상에 중점을 둡니다.

롱리드 시퀀싱 시장은 유전체 연구와 맞춤형 의료의 진전에 힘입어 현저한 성장을 이루고 있습니다. 시장 내에서는 시퀀싱 과정에서 시약 및 키트의 지속적인 수요에 힘입어 소모품 부문이 가장 높은 성장률을 보이고 있습니다. 장비 부문도 이어져 시퀀싱 플랫폼의 지속적인 혁신으로 데이터 정밀도 및 처리량이 향상되었습니다. 하위 부문 중에서는 롱리드 길이와 높은 정밀도를 제공하는 능력으로부터, 단일 분자 실시간 시퀀싱이 주도적 지위를 차지하고 있습니다. 나노포어 시퀀싱은 휴대성과 실시간 데이터 생성 능력에 의해 주목을 끌어 2위의 성장 부문이 되고 있습니다. 연구기관과 제약기업에서 시퀀싱 서비스의 외부 위탁이 확대되는 가운데, 서비스 부문도 견조한 성장을 보이고 있습니다. 종합적인 유전체 정보 수요가 높아짐에 따라 시퀀싱 기술과 바이오인포매틱스 솔루션의 지속적인 발전이 새로운 기회를 개척하고 미래의 진보를 견인함으로써 시장은 더욱 확대될 것으로 전망됩니다.

시장 세분화
유형별 단일 분자 실시간 시퀀싱, 나노포어 시퀀싱, 합성 롱리드 시퀀싱
제품별 장비, 소모품, 소프트웨어
서비스별 시퀀싱 서비스, 바이오인포매틱스 서비스
기술별 SMRT 시퀀싱, 나노포어 시퀀싱
용도별 전체 유전체 시퀀싱, 후성 유전학, 전사체학, 군유전체학, 구조 변이 검출
최종 사용자별 학술연구기관, 제약 및 바이오테크놀러지 기업, 병원 및 진료소
컴포넌트별 하드웨어, 소프트웨어
프로세스별 라이브러리 준비, 시퀀싱, 데이터 분석
전개 모드별 온프레미스, 클라우드 기반
모드별 연구 모드, 임상 모드

롱리드 시퀀싱 시장은 다양한 기업들이 경쟁하고 경쟁력 있는 가격 전략과 혁신적인 제품 투입을 통해 시장 점유율 확대를 도모하고 있는 특징이 있습니다. 기술 혁신이 급속히 진행되고 있으며 최첨단 시퀀싱 플랫폼의 도입이 가속화되고 있습니다. 이러한 혁신은 정확성 및 속도 향상을 목적으로 종합적인 유전체 분석에 대한 수요 증가에 대응하고 있습니다. 반면 가격 경쟁은 여전히 치열하며, 각 회사는 품질을 저하시키지 않고 비용 효율적인 솔루션을 제공하기 위해 노력하고 있습니다. 이러한 경쟁 구도는 제품 포트폴리오를 확대하고 세계 배포를 강화하기 위한 전략적 제휴와 파트너십을 통해 더욱 강화되고 있습니다. 경쟁 벤치마킹의 관점에서 주요 기업의 대부분은 기술력을 활용하여 경쟁 우위를 유지하고 있습니다. 규제 상황은 매우 중요하며 엄격한 지침이 제품 개발과 시장 진출 전략을 형성하고 있습니다. 북미와 유럽은 견고한 규제 프레임워크와 높은 도입률에 힘입어 최첨단을 달리고 있습니다. 아시아태평양은 의료 인프라와 조사 이니셔티브에 대한 투자 증가를 특징으로 하는 유망한 시장으로 부상하고 있습니다. 시퀀싱 기술의 진보와 맞춤형 의료에 대한 관심 증가를 배경으로 시장은 크게 성장할 것으로 예측됩니다. 규제 준수와 높은 운용 비용과 같은 과제는 남아 있지만, 혁신과 시장 확대의 가능성은 여전히 크다고 할 수 있습니다.

주요 동향 및 촉진요인 :

롱리드 시퀀싱 시장은 여러 역동적인 동향 및 촉진요인에 힘입어 견조한 성장을 이루고 있습니다. 하나의 중요한 동향은 종합적인 유전체 분석에 대한 수요가 증가하고 있으며, 롱리드 시퀀싱 기술이 유일무이한 형태로 이를 제공할 수 있습니다. 이러한 기술은 특히 복잡한 유전체 영역에서 타의 추종을 불허하는 정확성 및 인사이트를 제공하여 다양한 연구 및 임상 현장에서의 채택을 촉진합니다. 게다가, 바이오인포매틱스와 데이터 분석의 진보는 롱리드 시퀀싱의 유용성을 증가시키고 있습니다. 이들은 보다 효율적인 데이터 처리 및 해석을 가능하게 하고, 연구자들에게 이러한 기술을 보다 이용하기 쉽고, 가치 있는 것으로 하고 있습니다. 또한 시퀀싱과 관련된 비용이 낮아 액세스를 민주화하고 소규모 기관과 신흥 시장이 이러한 최첨단 솔루션에 투자할 수 있습니다. 또한, 상세한 유전 정보가 치료의 개별화에 필수적인 맞춤형 의료에 대한 중시 증가도 시장을 견인하고 있습니다. 롱리드 시퀀싱이 종합적인 유전체 발견을 제공하는 능력은 이러한 진화 분야에서 중요한 도구로서의 지위를 확립하고 있습니다. 게다가 학술기관과 산업 기업 간 연계가 혁신을 촉진하고 용도 분야를 확대함으로써 시장의 성장을 더욱 가속화하고 있습니다. 유전성 질환 증가 추세 및 정밀 진단 도구에 대한 수요는 또한 롱리드 시퀀싱 시장을 발전시키는 추가적인 촉진요인이 되었습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

  • 거시경제 분석
  • 시장 동향
  • 시장 성장 촉진요인
  • 시장 기회
  • 시장 성장 억제요인
  • CAGR : 성장 분석
  • 영향 분석
  • 신흥 시장
  • 기술 로드맵
  • 전략적 프레임워크

제4장 부문 분석

  • 시장 규모 및 예측 : 유형별
    • 단일 분자 실시간 시퀀싱
    • 나노포어 시퀀싱
    • 합성 롱리드 시퀀싱
  • 시장 규모 및 예측 : 제품별
    • 장치
    • 소모품
    • 소프트웨어
  • 시장 규모 및 예측 : 서비스별
    • 시퀀싱 서비스
    • 바이오인포매틱스 서비스
  • 시장 규모 및 예측 : 기술별
    • SMRT 시퀀싱
    • 나노포어 시퀀싱
  • 시장 규모 및 예측 : 용도별
    • 전체 유전체 시퀀싱
    • 후성 유전학
    • 전사체학
    • 군유전체학
    • 구조 변이 검출
  • 시장 규모 및 예측 : 최종 사용자별
    • 학술연구기관
    • 제약 및 바이오테크놀러지 기업
    • 병원 및 진료소
  • 시장 규모 및 예측 : 컴포넌트별
    • 하드웨어
    • 소프트웨어
  • 시장 규모 및 예측 : 프로세스별
    • 라이브러리 준비
    • 시퀀싱
    • 데이터 분석
  • 시장 규모 및 예측 : 전개 모드별
    • 온프레미스
    • 클라우드 기반
  • 시장 규모 및 예측 : 모드별
    • 연구 모드
    • 임상 모드

제5장 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 라틴아메리카
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카
  • 아시아태평양
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주
    • 대만
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 남아프리카
    • 서브 사하라 아프리카
    • 기타 중동 및 아프리카

제6장 시장 전략

  • 수요 및 공급의 갭 분석
  • 무역 및 물류 상의 제약
  • 가격, 비용 및 마진의 동향
  • 시장 침투
  • 소비자 분석
  • 규제 개요

제7장 경쟁 정보

  • 시장 포지셔닝
  • 시장 점유율
  • 경쟁 벤치마킹
  • 주요 기업의 전략

제8장 기업 프로파일

  • Pacific Biosciences
  • Oxford Nanopore Technologies
  • Genapsys
  • Stratos Genomics
  • Element Biosciences
  • Quantum-Si
  • Dovetail Genomics
  • Genome Transcriptome Facility of Bordeaux
  • Seq LL
  • Bionano Genomics
  • Tecan Genomics
  • Arima Genomics
  • 10x Genomics
  • Gencove
  • Twist Bioscience
  • Bio Skryb Genomics
  • Nu GEN Technologies
  • Longas Technologies
  • Loop Genomics
  • Base Genomics

제9장 당사에 대해서

AJY 26.03.31

Long Read Sequencing Market is anticipated to expand from $2.4 billion in 2024 to $9.1 billion by 2034, growing at a CAGR of approximately 12.2%. The Long Read Sequencing Market encompasses advanced genomic sequencing technologies that enable the reading of long DNA or RNA fragments, providing comprehensive insights into complex genetic structures. This market is driven by the demand for precision medicine, personalized healthcare, and research in genomics. Key applications include rare disease diagnosis, cancer genomics, and agricultural biotechnology. Innovations focus on improving accuracy, speed, and cost-effectiveness, addressing the needs of researchers and healthcare providers for detailed genetic information.

The Long Read Sequencing Market is experiencing significant growth, fueled by advancements in genomic research and personalized medicine. Within this market, the consumables segment is the top performer, driven by the recurring need for reagents and kits in sequencing processes. Instruments follow closely, with continuous innovations in sequencing platforms enhancing data accuracy and throughput. Among the sub-segments, single-molecule real-time sequencing is leading due to its capability to provide longer read lengths and higher accuracy. Nanopore sequencing is the second highest performing sub-segment, gaining traction for its portability and real-time data generation. The services segment is also witnessing robust growth, as outsourcing of sequencing services becomes more prevalent among research institutions and pharmaceutical companies. As the demand for comprehensive genomic insights rises, the market is poised for further expansion, with ongoing developments in sequencing technologies and bioinformatics solutions promising to unlock new opportunities and drive future advancements.

Market Segmentation
TypeSingle-Molecule Real-Time Sequencing, Nanopore Sequencing, Synthetic Long Read Sequencing
ProductInstruments, Consumables, Software
ServicesSequencing Services, Bioinformatics Services
TechnologySMRT Sequencing, Nanopore Sequencing
ApplicationWhole Genome Sequencing, Epigenetics, Transcriptomics, Metagenomics, Structural Variation Detection
End UserAcademic and Research Institutions, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics
ComponentHardware, Software
ProcessLibrary Preparation, Sequencing, Data Analysis
DeploymentOn-Premise, Cloud-Based
ModeResearch Mode, Clinical Mode

The Long Read Sequencing Market is characterized by a diverse array of players, each vying for increased market share through competitive pricing strategies and innovative product launches. The market is witnessing a surge in technological advancements, propelling the introduction of cutting-edge sequencing platforms. These innovations are designed to enhance accuracy and speed, catering to the growing demand for comprehensive genomic analysis. Meanwhile, pricing dynamics remain competitive, with companies striving to offer cost-effective solutions without compromising on quality. This competitive landscape is further intensified by strategic collaborations and partnerships aimed at expanding product portfolios and enhancing global reach. In terms of competition benchmarking, several key players are leveraging their technological prowess to maintain a competitive edge. The regulatory landscape is pivotal, with stringent guidelines shaping product development and market entry strategies. North America and Europe are at the forefront, driven by robust regulatory frameworks and high adoption rates. Asia-Pacific is emerging as a lucrative market, characterized by increasing investments in healthcare infrastructure and research initiatives. The market is poised for substantial growth, driven by advancements in sequencing technologies and the growing emphasis on personalized medicine. Challenges such as regulatory compliance and high operational costs persist, yet the potential for innovation and market expansion remains significant.

Geographical Overview:

The Long Read Sequencing Market is witnessing robust expansion across various regions, each presenting unique growth opportunities. North America leads this market, buoyed by extensive research initiatives and substantial funding. The presence of major biotechnology firms further accelerates market development. Europe follows, with a strong focus on genomics and personalized medicine, attracting significant investments and fostering innovation. In Asia Pacific, the market is growing rapidly, driven by technological advancements and increased healthcare expenditure. Countries like China and India are emerging as key players due to their expanding research capabilities and supportive government policies. Latin America is gaining traction, with rising investments in genomic research and a growing interest in precision medicine. The Middle East & Africa are also showing promise, with increasing awareness and adoption of advanced sequencing technologies. These regions are recognizing the potential of long read sequencing in advancing healthcare and research, thereby presenting lucrative opportunities for market players.

The global imposition of tariffs on biotechnology and sequencing equipment is influencing the Long Read Sequencing Market, particularly in East Asia. Japan and South Korea are navigating increased costs by fostering innovation in sequencing technologies and enhancing domestic capabilities. China's strategic pivot towards self-reliance is evident in its substantial investment in homegrown sequencing technology, mitigating impacts from Western trade barriers. Taiwan, while a pivotal player in semiconductor manufacturing, faces geopolitical vulnerabilities, potentially disrupting its supply chain continuity. The parent genomics market is witnessing robust growth, driven by advancements in personalized medicine and bioinformatics. By 2035, the market is poised for expansion, contingent on geopolitical stability and supply chain resilience. Meanwhile, Middle Eastern conflicts pose risks to global energy prices, indirectly affecting operational costs across the biotechnology sector.

Key Trends and Drivers:

The Long Read Sequencing Market is experiencing robust growth, propelled by several dynamic trends and drivers. One significant trend is the increasing demand for comprehensive genomic analysis, which long read sequencing technologies can uniquely provide. These technologies offer unparalleled accuracy and insight, particularly in complex genomic regions, driving their adoption in various research and clinical settings. Additionally, advancements in bioinformatics and data analytics are enhancing the utility of long read sequencing. They enable more efficient data processing and interpretation, making these technologies more accessible and valuable to researchers. Furthermore, decreasing costs associated with sequencing are democratizing access, allowing smaller institutions and emerging markets to invest in these cutting-edge solutions. The market is also driven by the growing emphasis on personalized medicine, where detailed genetic information is crucial for tailoring treatments. Long read sequencing's ability to deliver comprehensive genomic insights positions it as a critical tool in this evolving field. Moreover, collaborations between academic institutions and industry players are fostering innovation and expanding application areas, further fueling market growth. The increasing prevalence of genetic disorders and the need for precise diagnostic tools are additional drivers propelling the long read sequencing market forward.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Single-Molecule Real-Time Sequencing
    • 4.1.2 Nanopore Sequencing
    • 4.1.3 Synthetic Long Read Sequencing
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Consumables
    • 4.2.3 Software
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Sequencing Services
    • 4.3.2 Bioinformatics Services
    • 4.3.3 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 SMRT Sequencing
    • 4.4.2 Nanopore Sequencing
    • 4.4.3 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Whole Genome Sequencing
    • 4.5.2 Epigenetics
    • 4.5.3 Transcriptomics
    • 4.5.4 Metagenomics
    • 4.5.5 Structural Variation Detection
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Academic and Research Institutions
    • 4.6.2 Pharmaceutical and Biotechnology Companies
    • 4.6.3 Hospitals and Clinics
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Library Preparation
    • 4.8.2 Sequencing
    • 4.8.3 Data Analysis
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-Premise
    • 4.9.2 Cloud-Based
    • 4.9.3 Others
  • 4.10 Market Size & Forecast by Mode (2020-2035)
    • 4.10.1 Research Mode
    • 4.10.2 Clinical Mode
    • 4.10.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Process
      • 5.2.1.9 Deployment
      • 5.2.1.10 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Process
      • 5.2.2.9 Deployment
      • 5.2.2.10 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Process
      • 5.2.3.9 Deployment
      • 5.2.3.10 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Process
      • 5.3.1.9 Deployment
      • 5.3.1.10 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Process
      • 5.3.2.9 Deployment
      • 5.3.2.10 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Process
      • 5.3.3.9 Deployment
      • 5.3.3.10 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Process
      • 5.4.1.9 Deployment
      • 5.4.1.10 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Process
      • 5.4.2.9 Deployment
      • 5.4.2.10 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Process
      • 5.4.3.9 Deployment
      • 5.4.3.10 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Process
      • 5.4.4.9 Deployment
      • 5.4.4.10 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Process
      • 5.4.5.9 Deployment
      • 5.4.5.10 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Process
      • 5.4.6.9 Deployment
      • 5.4.6.10 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Process
      • 5.4.7.9 Deployment
      • 5.4.7.10 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Process
      • 5.5.1.9 Deployment
      • 5.5.1.10 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Process
      • 5.5.2.9 Deployment
      • 5.5.2.10 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Process
      • 5.5.3.9 Deployment
      • 5.5.3.10 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Process
      • 5.5.4.9 Deployment
      • 5.5.4.10 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Process
      • 5.5.5.9 Deployment
      • 5.5.5.10 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Process
      • 5.5.6.9 Deployment
      • 5.5.6.10 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Process
      • 5.6.1.9 Deployment
      • 5.6.1.10 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Process
      • 5.6.2.9 Deployment
      • 5.6.2.10 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Process
      • 5.6.3.9 Deployment
      • 5.6.3.10 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Process
      • 5.6.4.9 Deployment
      • 5.6.4.10 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Process
      • 5.6.5.9 Deployment
      • 5.6.5.10 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Pacific Biosciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Oxford Nanopore Technologies
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Genapsys
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Stratos Genomics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Element Biosciences
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Quantum- Si
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Dovetail Genomics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genome Transcriptome Facility of Bordeaux
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Seq LL
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Bionano Genomics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Tecan Genomics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Arima Genomics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 10x Genomics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Gencove
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Twist Bioscience
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Bio Skryb Genomics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Nu GEN Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Longas Technologies
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Loop Genomics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Base Genomics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제